Literature DB >> 17935793

Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity.

Paul A Nakonezny1, Matthew J Byerly, A John Rush.   

Abstract

This study examined the reliability and predictive validity of electronic monitoring (EM) in assessing the oral antipsychotic medication adherence of outpatients with schizophrenia or schizoaffective disorder. Sixty-one adult outpatients with schizophrenia or schizoaffective disorder who took a single oral antipsychotic medication were assessed monthly over a 6-month study period with EM of medication bottle opening. Symptom severity, as measured by the Positive and Negative Syndrome Scale (PANSS) total score, was assessed monthly over the 6-month study period. Cronbach's coefficient alpha revealed very high internal reliability (alpha=0.94). A high degree of test-retest reliability was found (beta ranged from 0.75 to 1.19 and r ranged from 0.63 to 0.90). As for predictive validity, greater mean EM adherence was significantly related to lower mean symptom severity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935793     DOI: 10.1016/j.psychres.2007.05.001

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  14 in total

1.  A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.

Authors:  Paul A Nakonezny; Carroll W Hughes; Taryn L Mayes; Kathryn H Sternweis-Yang; Betsy D Kennard; Matthew J Byerly; Graham J Emslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-10       Impact factor: 2.576

Review 2.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

3.  Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.

Authors:  Stephen J Tueller; Pascal R Deboeck; Richard A Van Dorn
Journal:  J Behav Med       Date:  2016-02-27

4.  Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China.

Authors:  Dong Roman Xu; Wenjie Gong; Steve Gloyd; Eric D Caine; Jane Simoni; James P Hughes; Shuiyuan Xiao; Wenjun He; Bofeng Dai; Meijuan Lin; Juan Nie; Hua He
Journal:  Schizophr Res       Date:  2018-05-26       Impact factor: 4.939

Review 5.  Measurement of psychiatric treatment adherence.

Authors:  Martha Sajatovic; Dawn I Velligan; Peter J Weiden; Marcia A Valenstein; Gbenga Ogedegbe
Journal:  J Psychosom Res       Date:  2009-07-25       Impact factor: 3.006

6.  The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia.

Authors:  Paul A Nakonezny; Matthew J Byerly; Amit Pradhan
Journal:  Psychiatry Res       Date:  2013-03-06       Impact factor: 3.222

7.  A brief adherence intervention that improved glycemic control: mediation by patterns of adherence.

Authors:  Heather F de Vries McClintock; Knashawn H Morales; Dylan S Small; Hillary R Bogner
Journal:  J Behav Med       Date:  2014-06-10

Review 8.  Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Authors:  Peter M Haddad; Cecilia Brain; Jan Scott
Journal:  Patient Relat Outcome Meas       Date:  2014-06-23

9.  Measuring concurrent oral hypoglycemic and antidepressant adherence and clinical outcomes.

Authors:  Hillary R Bogner; Heather F de Vries; Alison J O'Donnell; Knashawn H Morales
Journal:  Am J Manag Care       Date:  2013-03-01       Impact factor: 2.229

Review 10.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.